• Home
  • About Us
  • Our People
  • Pipeline
  • News
  • Contact Us
Home
  • Home
  • About Us
  • Our People
  • Pipeline
  • News
  • Contact Us

Archives

Monthly Archive for: "July, 2021"
Home /
0
By Jane Moate
In News
Posted 7th July 2021

NeRRe Therapeutics raises £20 million in a Series B2 financing round

READ MORE

NeRRe Logo

NeRRe Therapeutics is a UK based clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity.

Useful Links
  • Contact Us
  • About Us
  • Privacy Policy
  • Cookie Notice
  • Terms & Conditions
  • Clinical Trials Privacy Notice
Contact Us
  • NeRRe Therapeutics
  • +44 (0) 1438 906 960
  • info@nerretherapeutics.com
  • www.nerretherapeutics.com
© 2018 NeRRe Therapeutics. All rights reserved. Website design by FDM Digital
Contact Us

Please fill out the form to get in touch with us.

Not readable? Change text. captcha txt

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

More information about our Cookie Policy